CTIS2023-508292-37-00进行中（未招募）1 期
A randomized double-blind, placebo-controlled, multicenter trial assessing the impact of lipoprotein (a) lowering with pelacarsen (TQJ230) on major cardiovascular events in patients with established cardiovascular disease - CTQJ230A12301
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 8,323
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Lp(a) = 70 mg/dL at the screening visit, Optimal LDL-cholesterol lowering treatment, Optimal treatment of other CV risk factors, Myocardial infarction: = 3 months from screening and randomization visits to = 10 years prior to the screening visit, and/or, Ischemic stroke: = 3 months from screening and randomization visits to = 10 years prior to the screening visit, and/or, Clinically significant symptomatic peripheral artery disease
排除标准
- •Uncontrolled hypertension, Heart failure New York Heart Association (NYHA) class IV, History of malignancy of any organ system, History of hemorrhagic stroke or other major bleeding, Platelet count <140,000 per mm3, Active liver disease or hepatic dysfunction, Significant kidney disease, Pregnant or nursing women
研究者
相似试验
进行中（未招募）
1 期
A multicenter trial assessing the impact of lipoprotein (a) lowering with pelacarsen (TQJ230) on major cardiovascular events in patients with cardiovascular disease.MedDRA version: 21.1Level: LLTClassification code 10051614Term: Arteriosclerotic cardiovascular diseaseSystem Organ Class: 100000004866Cardiovascular DiseaseEUCTR2019-001076-11-BGovartis Pharma AG8,280
进行中（未招募）
1 期
A multicenter trial assessing the impact of lipoprotein (a) lowering with pelacarsen (TQJ230) on major cardiovascular events in patients with cardiovascular disease.MedDRA version: 21.1Level: LLTClassification code 10051614Term: Arteriosclerotic cardiovascular diseaseSystem Organ Class: 100000004866Cardiovascular DiseaseEUCTR2019-001076-11-PTovartis Pharma AG7,680
进行中（未招募）
1 期
A multicenter trial assessing the impact of lipoprotein (a) lowering with TQJ230 on major cardiovascular events in patients with cardiovascular disease.MedDRA version: 21.1Level: LLTClassification code 10051614Term: Arteriosclerotic cardiovascular diseaseSystem Organ Class: 100000004866Cardiovascular DiseaseEUCTR2019-001076-11-ITovartis Pharma AG7,680
进行中（未招募）
1 期
A multicenter trial assessing the impact of lipoprotein (a) lowering with pelacarsen (TQJ230) on major cardiovascular events in patients with cardiovascular disease.Cardiovascular DiseaseEUCTR2019-001076-11-DKovartis Pharma AG8,280
进行中（未招募）
1 期
A multicenter trial assessing the impact of lipoprotein (a) lowering with pelacarsen (TQJ230) on major cardiovascular events in patients with cardiovascular disease.MedDRA version: 21.1Level: LLTClassification code 10051614Term: Arteriosclerotic cardiovascular diseaseSystem Organ Class: 10047065 - Vascular disordersCardiovascular DiseaseEUCTR2019-001076-11-SIovartis Pharma AG8,280